Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 1, Pages 43-57Publisher
EXPERT REVIEWS
DOI: 10.1586/ERN.09.143
Keywords
antipsychotic medication; biomarker; cognition; neuropsychology; schizophrenia
Categories
Funding
- Janssen
- NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH072767, K08MH083888] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest cognitive benefits relative to first-generation antipsychotics. This might reflect a limited drug effect in humans, a differential drug effect due to brain alterations associated with schizophrenia, or limited sensitivity of the neuropsychological tests for evaluating cognitive outcomes. New adjunctive procognitive drugs may be needed to achieve robust cognitive and functional improvement. Drug discovery may benefit from greater utilization of translational neurocognitive biomarkers to bridge preclinical and clinical proof-of-concept studies, to optimize assay sensitivity, enhance cost efficiency, and speed progress in drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available